BridgeBio Pharma, Inc.
3160 Porter Drive
Suite 250
Palo Alto, CA 94304
United States
650 391 9740
https://bridgebio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 550
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Neil Kumar Ph.D. | Co-Founder, President, CEO & Director | 1.53M | 無 | 1979 |
| Dr. Charles J. Homcy M.D. | Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director | 563.2k | 無 | 1948 |
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Chairman of Oncology & Director | 542.78k | 無 | 1950 |
| Dr. Brian C. Stephenson C.F.A., Ph.D. | CFO & Secretary | 1.15M | 無 | 1981 |
| Dr. Richard H. Scheller Ph.D. | Chairman of Research & Development | 509.62k | 無 | 1953 |
| Dr. Uma Sinha Ph.D. | Chief Scientific Officer | 1.31M | 無 | 1958 |
| Grace Rauh | Vice President of Communications | 無 | 無 | 無 |
| Mr. Eli M. Wallace Ph.D. | Chief Scientific Officer of Oncology | 無 | 無 | 1967 |
| Dr. Thomas Trimarchi Ph.D. | Chief Product Officer | 無 | 無 | 無 |
| Dr. Eric Michael David J.D., M.D., Ph.D. | Chief Executive Officer of Gene Therapy | 無 | 無 | 1972 |
描述
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
公司管治
截至 2024年4月1日 止，BridgeBio Pharma, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：3；董事會：10；股東權利：8；現金賠償：10。
